183 related articles for article (PubMed ID: 7795587)
1. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations.
Little M; Holmes G; Bickmore W; van Heyningen V; Hastie N; Wainwright B
Hum Mol Genet; 1995 Mar; 4(3):351-8. PubMed ID: 7795587
[TBL] [Abstract][Full Text] [Related]
2. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
3. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
4. WT1 mutations in patients with Denys-Drash syndrome: a novel mutation in exon 8 and paternal allele origin.
Nordenskjöld A; Friedman E; Anvret M
Hum Genet; 1994 Feb; 93(2):115-20. PubMed ID: 8112732
[TBL] [Abstract][Full Text] [Related]
5. Role for first zinc finger of WT1 in DNA sequence specificity: Denys-Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites.
Wang D; Horton JR; Zheng Y; Blumenthal RM; Zhang X; Cheng X
Nucleic Acids Res; 2018 May; 46(8):3864-3877. PubMed ID: 29294058
[TBL] [Abstract][Full Text] [Related]
6. Donor splice-site mutations in WT1 are responsible for Frasier syndrome.
Barbaux S; Niaudet P; Gubler MC; Grünfeld JP; Jaubert F; Kuttenn F; Fékété CN; Souleyreau-Therville N; Thibaud E; Fellous M; McElreavey K
Nat Genet; 1997 Dec; 17(4):467-70. PubMed ID: 9398852
[TBL] [Abstract][Full Text] [Related]
7. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.
Little MH; Williamson KA; Mannens M; Kelsey A; Gosden C; Hastie ND; van Heyningen V
Hum Mol Genet; 1993 Mar; 2(3):259-64. PubMed ID: 8388765
[TBL] [Abstract][Full Text] [Related]
8. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms.
Klamt B; Koziell A; Poulat F; Wieacker P; Scambler P; Berta P; Gessler M
Hum Mol Genet; 1998 Apr; 7(4):709-14. PubMed ID: 9499425
[TBL] [Abstract][Full Text] [Related]
9. Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one.
Ladomery M; Sommerville J; Woolner S; Slight J; Hastie N
J Cell Sci; 2003 Apr; 116(Pt 8):1539-49. PubMed ID: 12640038
[TBL] [Abstract][Full Text] [Related]
10. A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome.
Patek CE; Little MH; Fleming S; Miles C; Charlieu JP; Clarke AR; Miyagawa K; Christie S; Doig J; Harrison DJ; Porteous DJ; Brookes AJ; Hooper ML; Hastie ND
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2931-6. PubMed ID: 10077614
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.
Pelletier J; Bruening W; Kashtan CE; Mauer SM; Manivel JC; Striegel JE; Houghton DC; Junien C; Habib R; Fouser L
Cell; 1991 Oct; 67(2):437-47. PubMed ID: 1655284
[TBL] [Abstract][Full Text] [Related]
12. Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1.
Zhai G; Iskandar M; Barilla K; Romaniuk PJ
Biochemistry; 2001 Feb; 40(7):2032-40. PubMed ID: 11329270
[TBL] [Abstract][Full Text] [Related]
13. Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation.
Hewitt SM; Fraizer GC; Wu YJ; Rauscher FJ; Saunders GF
J Biol Chem; 1996 Apr; 271(15):8588-92. PubMed ID: 8621487
[TBL] [Abstract][Full Text] [Related]
14. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database.
Jeanpierre C; Denamur E; Henry I; Cabanis MO; Luce S; Cécille A; Elion J; Peuchmaur M; Loirat C; Niaudet P; Gubler MC; Junien C
Am J Hum Genet; 1998 Apr; 62(4):824-33. PubMed ID: 9529364
[TBL] [Abstract][Full Text] [Related]
15. No evidence of WT1 involvement in a Burkitt's lymphoma in a patient with Denys-Drash syndrome.
Perotti D; Mondini P; Giardini R; Ferrari A; Massimino M; Gambirasio F; Pierotti MA; Fossati-Bellani F; Radice P
Ann Oncol; 1998 Jun; 9(6):627-31. PubMed ID: 9681076
[TBL] [Abstract][Full Text] [Related]
16. Mother-to-child transmitted WT1 splice-site mutation is responsible for distinct glomerular diseases.
Denamur E; Bocquet N; Mougenot B; Da Silva F; Martinat L; Loirat C; Elion J; Bensman A; Ronco PM
J Am Soc Nephrol; 1999 Oct; 10(10):2219-23. PubMed ID: 10505700
[TBL] [Abstract][Full Text] [Related]
17. The human sex-determining gene SRY is a direct target of WT1.
Hossain A; Saunders GF
J Biol Chem; 2001 May; 276(20):16817-23. PubMed ID: 11278460
[TBL] [Abstract][Full Text] [Related]
18. Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor.
Tajinda K; Carroll J; Roberts CT
Endocrinology; 1999 Oct; 140(10):4713-24. PubMed ID: 10499530
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter.
Webster NJ; Kong Y; Sharma P; Haas M; Sukumar S; Seely BL
Biochem Mol Med; 1997 Dec; 62(2):139-50. PubMed ID: 9441865
[TBL] [Abstract][Full Text] [Related]
20. RNA binding by the Wilms tumor suppressor zinc finger proteins.
Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
